HOOK Stock Overview
A clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
HOOKIPA Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.82 |
| 52 Week High | US$10.50 |
| 52 Week Low | US$0.82 |
| Beta | 0.77 |
| 1 Month Change | -35.04% |
| 3 Month Change | -56.35% |
| 1 Year Change | -90.29% |
| 3 Year Change | -95.31% |
| 5 Year Change | -98.95% |
| Change since IPO | -99.41% |
Recent News & Updates
Recent updates
The Market Doesn't Like What It Sees From HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Revenues Yet As Shares Tumble 26%
Dec 21
Companies Like HOOKIPA Pharma (NASDAQ:HOOK) Could Be Quite Risky
Nov 19HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 26% Dip In Price Shows Sentiment Is Matching Revenues
Sep 27The Market Doesn't Like What It Sees From HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Revenues Yet As Shares Tumble 29%
Aug 13Why Investors Shouldn't Be Surprised By HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 34% Share Price Plunge
Jun 22HOOKIPA Pharma Inc. (NASDAQ:HOOK) Shares Fly 25% But Investors Aren't Buying For Growth
Apr 28Analysts Just Made A Major Revision To Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenue Forecasts
Mar 24Need To Know: The Consensus Just Cut Its HOOKIPA Pharma Inc. (NASDAQ:HOOK) Estimates For 2023
Aug 11HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Just Slashed This Year's Revenue Estimates By 17%
May 16Is HOOKIPA Pharma (NASDAQ:HOOK) A Risky Investment?
Apr 26Need To Know: Analysts Are Much More Bullish On HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenues
Nov 19HOOKIPA wins FDA nod to start clinical studies for prostate cancer therapy
Jul 25Shareholder Returns
| HOOK | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -23.6% | -9.9% | -9.4% |
| 1Y | -90.3% | -14.6% | -3.4% |
Return vs Industry: HOOK underperformed the US Biotechs industry which returned -14.6% over the past year.
Return vs Market: HOOK underperformed the US Market which returned -3.4% over the past year.
Price Volatility
| HOOK volatility | |
|---|---|
| HOOK Average Weekly Movement | 12.0% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 7.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.7% |
Stable Share Price: HOOK's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: HOOK's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 85 | Malte Peters | www.hookipapharma.com |
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company’s immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer. It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial.
HOOKIPA Pharma Inc. Fundamentals Summary
| HOOK fundamental statistics | |
|---|---|
| Market cap | US$10.35m |
| Earnings (TTM) | -US$43.50m |
| Revenue (TTM) | US$43.95m |
0.2x
P/S Ratio-0.2x
P/E RatioIs HOOK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HOOK income statement (TTM) | |
|---|---|
| Revenue | US$43.95m |
| Cost of Revenue | US$67.13m |
| Gross Profit | -US$23.19m |
| Other Expenses | US$20.32m |
| Earnings | -US$43.50m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.47 |
| Gross Margin | -52.76% |
| Net Profit Margin | -98.99% |
| Debt/Equity Ratio | 0% |
How did HOOK perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/07 17:01 |
| End of Day Share Price | 2025/04/04 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
HOOKIPA Pharma Inc. is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Douglas Buchanan | Citizens JMP Securities, LLC |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |